|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Early Toxicity Rates** | **Late Toxicity Rates** |
|  | **Grade** | **C-SRT****PB****+ePLNs****(n=13)** | **DE-SRT****PB/SIB****+ePLNs****(n=11)** | **DE-SRT****PB/SIB+****ePLNs/SIB****(n=15)** | **DE-SRT****PB+****ePLNs/SIB****(n=16)** | **DE-SRT****ePLNs/SIB****(n=3)** | **C-SRT****PB****+ePLNs****(n=11)** | **DE-SRT****PB/SIB****+ePLNs****(n=8)** | **DE-SRT****PB/SIB+****ePLNs/SIB****(n=11)** | **DE-SRT****PB+****ePLNs/SIB****(n=12)** | **DE-SRT****ePLNs/SIB****(n=4)** |
| **Rectal Bleeding** | **1** | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (6.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (8.3%) | 0 (0.0%) |
| **3** | 1 (7.7%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 1 (8.3%) | 0 (0.0%) |
| **Proctitis** | **1** | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 2 (3.2%) | 0 (0.0%) | 3 (27.3%) | 2 (16.7%) | 0 (0.0%) |
| **2** | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.6%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| **Stool Incontinence** | **1** | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (8.3%) | 0 (0.0%) |
| **Hematuria** | **1** | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | 0 (0.0%) |
| **Cystitis** | **1** | 0 (0.0%) | 2 (18.2%) | 1 (6.7%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | 0 (0.0%) |
| **Genitourinary Fistula** | **2** | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | 0 (0.0%) | 0 (0.0%) |
| **Urine Incontinence** | **1** | 3 (23.1%) | 3 (27.3%) | 0 (0.0%) | 1 (6.3%) | 2 (66.7%) | 6 (54.5%) | 1 (12.5%) | 3 (27.3%) | 4 (33.3%) | 2 (50%) |
| **2** | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (12.5%) | 2 (18.2%) | 1 (8.3%) | 0 (0.0%) |
| **3** | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (33.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (25.0%) |
| **Urinary Obstruction** | **1** | 0 (0.0%) | 1 (9.1%) | 1(6.7%) | 1 (6.3%) | 0 (0.0%) | 0 (0.0%) | 1 (12.5%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| **3** | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (8.3%) | 0 (0.0%) |
| **Erectile Dysfunction** | **1** | 0 (0.0%) | 1 (9.1%) | 1(6.7%) | 1 (6.3%) | 0 (0.0%) | 0 (0.0%) | 1 (12.5%) | 0 (0.0%) | 1 (8.3%) | 0 (0.0%) |
| **2** | 2 (15.4%) | 0 (0.0%) | 0 (0.0%) | 1 (6.3%) | 0 (0.0%) | 1 (9.1%) | 1 (12.5%) | 1 (9.1%) | 1 (8.3%) | 0 (0.0%) |
| **3** | 1 (7.7%) | 1 (9.1%) | 2 (13.3%) | 1 (6.3%) | 0 (0.0%) | 3 (27.3%) | 0 (0.0%) | 3 (25.0%) | 1 (8.3%) | 0 (0.0%) |

**Supplementary Table 1:** Comparison of newly diagnosed or worsened early (<6 months) and late (>6 months) toxicity rates for the subgroups: C-SRT (PB+ePLNs) and DE-SRT (PB/SIB+ePLNs, PB/SIB+ePLNs/SIB, PB+ ePLNs/SIB, and ePLNs/SIB).

Side effects were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 [15]. (C-SRT= conventional salvage radiotherapy, DE-SRT= dose-escalated radiotherapy, PB= prostate bed, SIB= simultaneously integrated boost, ePLNs= elective pelvic lymph nodes)